Key result
Non-sarcomeric causes, including RASopathies and metabolic disorders, represent up to 35% of pediatric hypertrophic cardiomyopathy cases and require specific etiological diagnosis for targeted management.
Why the study?
Non-sarcomeric etiologies represent up to 35% of pediatric HCM cases and carry distinct prognoses, making etiological diagnosis essential for targeted management and therapy.
This review highlights the importance of identifying non-sarcomeric etiologies in pediatric hypertrophic cardiomyopathy, which account for up to 35% of cases, to guide targeted management and therapy.
No takes yet. Share an insight, caveat, or question.
Pediatric HCM requires etiology-specific evaluation beyond sarcomeric genes; leaves open targeted therapies for non-sarcomeric forms.
Monda et al. (2021) conducted a review in Hypertrophic Cardiomyopathy (Non-sarcomeric Causes). Non-sarcomeric causes, including RASopathies and metabolic disorders, represent up to 35% of pediatric hypertrophic cardiomyopathy cases and require specific etiological diagnosis for targeted management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: